Indirubin

Inhibitor of CDK and GSK



ALX-270-361-M001	1 mg	50.00 USD

ALX-270-361-M005	5 mg	216.00 USD

Replaces Prod. #: BML-CC206

Inhibitor of cyclin-dependent kinases (CDK1/cyclin B (IC₅₀=10µM), CDK2/cyclin A (IC₅₀=2.2µM), CDK2/cyclin E (IC₅₀=7.5µM), CDK4/cyclin D1 (IC₅₀=12µM), CDK5/p35 (IC₅₀=5.5µM)) and of GSK-3β (IC₅₀=600nM). Inhibits inflammatory reaction in delayed-type hypersensitivity in mice. Ligand of human aryl hydrocarbon receptor. Exhibits anti-cancer activity.

Product Specification

Identity:	Identity determined by ¹H-NMR, ¹³C-NMR, IR, ESI-MS and UV.

Formula:	C₁₆H₁₀N₂O₂

MW:	262.3

Purity:	≥98% (¹H-NMR, HPLC)

Appearance:	Purple powder.

CAS:	479-41-4

Source/Host:	Synthetic.

Solubility:	Soluble in DMSO (10mg/ml) or methanol (0.3mg/ml); sparingly soluble in aqueous buffers (12.5µg/ml).

Long Term Storage:	+4°C

Use/Stability:	Stable for at least 2 years when stored at +4°C in the dark. Stock solutions should be stored in the dark and used within 1 month.

Handling:	Keep cool and dry. Protect from light.

Background / Technical Information:	Indirubin is derived from various natural sources, such as Indigofera indica, Isatis tinctoria and I. indigotica by fermentation, oxidation and the presence of light as a by product of indigo formation. Indirubin is also present in human urine and fetal bovine serum. Preclinical studies of indirubin its confirmed anti-tumor activity. Efficacy against chronic myelocytic leukemia was demonstrated in clinical trials in China.

Please mouse over

Product Literature References

Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway: G. Sethi, et al.; J. Biol. Chem. 281, 23425 (2006), Abstract;

Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine: G. Eisenbrand, et al.; J. Cancer Res. Clin. Oncol. 130, 627 (2004), Abstract;

Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine: J. Adachi, et al.; J. Biol. Chem. 276, 31475 (2001), Abstract; Full Text

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin-dependent kinase inhibitors?: S. Leclerc, et al.; J. Biol. Chem. 276, 251 (2001), Abstract; Full Text

Indirubin inhibits inflammatory reactions in delayed-type hypersensitivity: T. Kunikata, et al.; Eur. J. Pharmacol. 410, 93 (2000), Abstract;

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases: R. Hoessel, et al.; Nature Cell Biol. 1, 60 (1999), Abstract;